FDA Needs Better Postmarket Data, Not More Postmarket Authority – Schultz
This article was originally published in The Gray Sheet
FDA should establish a permanent network of hospitals to collect device postmarket data while lowering the evidence standard for market approval, Harvard Clinical Research Institute Chief Scientific Officer Richard Kuntz, MD, suggests
You may also be interested in...
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.